Biggest change(2) Deferred implementation costs is excluded from Adjusted Partner Share and other third-party costs as follows (in thousands): Year Ended December 31, 2021 Cardlytics Platform Bridg Platform Consolidated Partner Share and other third-party costs $ 140,864 $ 409 $ 141,273 Minus: Deferred implementation costs 3,785 — 3,785 Adjusted Partner Share and other third-party costs $ 137,079 $ 409 $ 137,488 46 Adjusted EBITDA The following table presents a reconciliation of Adjusted EBITDA to Net Loss, the most directly comparable GAAP measure, for each of the periods indicated (in thousands): Year Ended December 31, 2023 2022 2021 Net Loss $ (134,702) $ (465,264) $ (128,565) Plus: Interest expense, net 2,336 2,556 12,563 Depreciation and amortization 26,460 37,544 29,871 Stock-based compensation expense 40,980 44,686 50,264 Acquisition, integration and divestiture (benefits) costs (6,313) (2,874) 24,372 Change in fair value of contingent consideration 1,246 (128,174) 1,374 Foreign currency (gain) loss (3,304) 6,376 1,267 Impairment of goodwill and intangible assets 70,518 453,288 — Loss on divestiture 6,550 — — Restructuring and reduction of force — 8,139 713 Income tax benefit — (1,446) (7,864) Deferred implementation costs — — 3,785 Adjusted EBITDA $ 3,771 $ (45,169) $ (12,220) 47 The following table presents a reconciliation of Adjusted EBITDA to Adjusted Contribution, the most directly comparable segment income measure, for each of the periods indicated (in thousands): Year Ended December 31, 2023 2022 2021 Consolidated Adjusted Contribution $ 158,626 $ 143,034 $ 129,628 Minus: Delivery costs 28,248 30,402 22,503 Sales and marketing expense 57,425 74,745 65,996 Research and development expense 51,352 54,435 38,104 General and administration expense 58,810 81,446 66,222 Stock-based compensation expense (40,980) (44,686) (50,264) Restructuring and reduction of force — (8,139) (713) Adjusted EBITDA $ 3,771 $ (45,169) $ (12,220) Cardlytics platform Adjusted Contribution $ 135,518 $ 122,981 $ 121,675 Minus: Delivery costs 21,447 24,112 18,170 Sales and marketing expense 48,671 67,830 62,771 Research and development expense 45,746 47,579 35,393 General and administration expense 56,542 79,069 63,379 Stock-based compensation expense (37,782) (43,490) (47,223) Restructuring and reduction of force — (8,139) (713) Adjusted EBITDA $ 894 $ (43,980) $ (10,102) Bridg platform Adjusted Contribution $ 23,108 $ 20,053 $ 7,953 Minus: Delivery costs 6,801 6,290 4,333 Sales and marketing expense 8,754 6,915 3,225 Research and development expense 5,606 6,856 2,711 General and administration expense 2,268 2,377 2,843 Stock-based compensation expense (3,198) (1,196) (3,041) Restructuring and reduction of force — — — Adjusted EBITDA $ 2,877 $ (1,189) $ (2,118) 48 Adjusted Net Loss The following table presents a reconciliation of Adjusted Net Loss to Net Loss, the most directly comparable GAAP measure, for each of the periods indicated (in thousands): Year Ended December 31, 2023 2022 2021 Net Loss $ (134,702) $ (465,264) $ (128,565) Plus: Stock-based compensation expense 40,980 44,686 50,264 Foreign currency (gain) loss (3,304) 6,376 1,267 Acquisition, integration and divestiture (benefits) costs (6,313) (2,874) 24,372 Amortization of acquired intangibles 13,589 25,019 19,712 Change in fair value of contingent consideration 1,246 (128,174) 1,374 Impairment of goodwill and intangible assets 70,518 453,288 — Loss on divestiture 6,550 — — Restructuring and reduction of force — 8,139 713 Income tax benefit — (1,446) (7,864) Adjusted Net Loss $ (11,436) $ (60,250) $ (38,727) Weighted-average number of shares of common stock used in computing Adjusted net loss per share: Weighted-average common shares outstanding, diluted 36,488 33,419 32,202 Adjusted weighted-average common shares outstanding, diluted 36,488 33,419 32,202 Adjusted Net Loss per share attributable to common stockholders, diluted $ (0.31) $ (1.80) $ (1.20) Free Cash Flow The following is a reconciliation of free cash flow to the most comparable GAAP measure, net cash used in operating activities (in thousands): Year Ended December 31, 2023 2022 2021 Net cash used in operating activities $ (185) $ (53,904) $ (38,523) Plus: Acquisition of property and equipment (667) (1,171) (3,108) Acquisition of patents — (175) (133) Capitalized software development costs (11,725) (12,140) (9,323) Free Cash Flow $ (12,577) $ (67,390) $ (51,087) Components of Results of Operations Revenue We sell our Cardlytics platform solution by entering into agreements directly with marketers or their marketing agencies, generally through the execution of insertion orders.
Biggest changeBillings increased by $10.9 million during 2023 compared to 2022, primarily driven by an increase of $32.8 million in sales to new marketers, offset by a $21.9 million decrease in sales to existing marketers. 43 The following table presents a reconciliation of billings to revenue, the most directly comparable GAAP measure, for each of the periods indicated (in thousands): Year Ended December 31, 2024 2023 2022 Consolidated Revenue $ 278,298 $ 309,204 $ 298,542 Plus: Consumer Incentives 165,542 144,222 143,935 Billings $ 443,840 $ 453,426 $ 442,477 Cardlytics platform Revenue $ 255,615 $ 285,425 $ 277,185 Plus: Consumer Incentives 165,542 144,222 143,935 Billings $ 421,157 $ 429,647 $ 421,120 Bridg platform Revenue $ 22,683 $ 23,779 $ 21,357 Plus: Consumer Incentives — — — Billings $ 22,683 $ 23,779 $ 21,357 Adjusted Contribution The following table presents a reconciliation of Adjusted Contribution to gross profit, the most directly comparable GAAP measure, for each of the periods indicated (in thousands): Year Ended December 31, 2024 2023 2022 Revenue $ 278,298 $ 309,204 $ 298,542 Minus: Partner Share and other third-party costs 127,761 150,578 155,507 Delivery costs (1) 29,643 28,248 30,403 Gross Profit 120,894 130,378 112,632 Plus: Delivery costs (1) 29,643 28,248 30,403 Adjusted Contribution $ 150,537 $ 158,626 $ 143,035 (1) Stock-based compensation expense recognized in delivery costs totaled $2.7 million, $2.4 million and $2.7 million during 2024, 2023 and 2022, respectively. 44 Adjusted EBITDA The following table presents a reconciliation of Adjusted EBITDA to Net Loss, the most directly comparable GAAP measure, for each of the periods indicated (in thousands): Year Ended December 31, 2024 2023 2022 Net Loss $ (189,304) $ (134,702) $ (465,264) Plus: Interest expense, net 5,553 2,336 2,556 Depreciation and amortization 25,689 26,460 37,544 Stock-based compensation expense 40,367 40,980 44,686 Acquisition, integration and divestiture costs (benefits) 161 (6,313) (2,874) Change in contingent consideration 210 1,246 (128,174) Foreign currency loss (gain) 1,269 (3,304) 6,376 Impairment of goodwill and intangible assets 131,595 70,518 453,288 Gain on debt extinguishment (13,017) — — Loss on divestiture — 6,550 — Restructuring and reduction of force — — 8,139 Income tax benefit — — (1,446) Adjusted EBITDA $ 2,523 $ 3,771 $ (45,169) Adjusted Net Loss The following table presents a reconciliation of Adjusted Net Loss to Net Loss, the most directly comparable GAAP measure, for each of the periods indicated (in thousands): Year Ended December 31, 2024 2023 2022 Net Loss $ (189,304) $ (134,702) $ (465,264) Plus: Stock-based compensation expense 40,367 40,980 44,686 Foreign currency loss (gain) 1,269 (3,304) 6,376 Acquisition, integration and divestiture costs (benefits) 161 (6,313) (2,874) Amortization of acquired intangibles 9,810 13,589 25,019 Change in contingent consideration 210 1,246 (128,174) Impairment of goodwill and intangible assets 131,595 70,518 453,288 Gain on debt extinguishment (13,017) — — Loss on divestiture — 6,550 — Restructuring and reduction of force — — 8,139 Income tax benefit — — (1,446) Adjusted Net Loss $ (18,909) $ (11,436) $ (60,250) Weighted-average number of shares of common stock used in computing Adjusted net loss per share: Weighted-average common shares outstanding, diluted 48,361 36,488 33,419 Adjusted Net Loss per share, diluted $ (0.39) $ (0.31) $ (1.80) 45 Free Cash Flow The following is a reconciliation of free cash flow to the most comparable GAAP measure, net cash used in operating activities (in thousands): Year Ended December 31, 2024 2023 2022 Net cash used in operating activities $ (8,824) $ (185) $ (53,904) Plus: Acquisition of property and equipment (1,562) (667) (1,171) Acquisition of patents — — (175) Capitalized software development costs (17,736) (11,725) (12,140) Free Cash Flow $ (28,122) $ (12,577) $ (67,390) Components of Results of Operations Revenue We sell our Cardlytics platform solution by entering into agreements directly with marketers or their marketing agencies, generally through the execution of insertion orders.
Partner Share costs are included in Partner Share and other third-party costs in our consolidated statements of operations, rather than as a reduction of revenue, because we and not our partners act as the principal in our arrangements with marketers. We run campaigns offering compelling Consumer Incentives to drive an expected rate of return on advertising spend for marketers.
Partner Share costs are included in Partner Share and other third-party costs in our consolidated statements of operations, rather than as a reduction of Revenue, because we and not our partners act as the principal in our arrangements with advertisers. We run campaigns offering compelling Consumer Incentives to drive an expected rate of return on advertising spend for marketers.
Delivery costs also include hosting costs, purchased or licensed software costs, outsourcing costs and professional services costs. As we continue to migrate our technology to the cloud, our delivery costs will increase in absolute dollars and if such anticipated revenue growth does not occur, our delivery costs as a percentage of revenue will be adversely affected.
Delivery costs also include hosting costs, purchased or licensed software costs, outsourcing costs and professional services costs. As we continue to migrate our technology to the cloud, we expect our delivery costs will increase in absolute dollars and if such anticipated Revenue growth does not occur, our delivery costs as a percentage of Revenue will be adversely affected.
Triggering events that may indicate impairment include, but are not limited to, a significant adverse change in customer demand or business climate or a significant d ecrease in expected cash flows. Loss on Divestiture Loss on divestiture of businesses consists of loss on the sale of a business during the year ended December 31, 2023.
Triggering events that may indicate impairment include, but are not limited to, a significant adverse change in customer demand or business climate or a significant d ecrease in expected cash flows. 47 Loss on divestiture Loss on divestiture of businesses consists of loss on the sale of a business during the year ended December 31, 2023.
We define Adjusted Net Loss per share as Adjusted Net Loss divided by our weighted-average common shares outstanding, diluted. Free Cash Flow We define Free Cash Flow as net cash provided by (used in) operating activities, plus acquisition of property and equipment, acquisition of patents and capitalized software development costs.
We define Adjusted Net Loss per share as Adjusted Net Loss divided by our weighted-average common shares outstanding, diluted. Free Cash Flow We define Free Cash Flow as net cash used in operating activities, plus acquisition of property and equipment, capitalized software development costs and acquisition of patents.
Over time, we expect delivery costs will decline as a percentage of revenue. Sales and Marketing Expense Sales and marketing expense consists primarily of personnel costs of our sales, account management, marketing and analytics teams, including salaries, benefits, bonuses, commissions, stock-based compensation and payroll taxes.
Over time, we expect delivery costs will decline as a percentage of Revenue. 46 Sales and Marketing Expense Sales and marketing expense consists primarily of personnel costs of our sales, account management, marketing and analytics teams, including salaries, benefits, bonuses, commissions, stock-based compensation and payroll taxes.
At times, we may collaborate with a partner to enhance the level of Consumer Incentives to their respective customers, funded by their Partner Share. We believe that these investments by our partners positively impact our platforms by making their customers more highly engaged with our platforms.
At times, we may collaborate with a partner to enhance the level of Consumer Incentives to their respective customers, funded by their Partner Share. We believe that these investments by our partners positively impact our platform by making their customers more highly engaged with our platforms.
This amendment also extended the maturity date of the 2018 Loan Facility from December 31, 2022 to April 29, 2024, and further stated that if we had positive Adjusted EBITDA by December 31, 2023, we could extend the maturity date of the loan to April 29, 2025.
This amendment also extended the maturity date of the 2018 Loan Facility from December 31, 2022 to April 29, 2024, and further stated that if we had positive Adjusted EBITDA by December 31, 2024, we could extend the maturity date of the loan to April 29, 2025.
However, these investments negatively impact our GAAP revenue, which is reported net of Consumer Incentives. 41 Non-GAAP Measures and Other Performance Metrics We regularly monitor a number of financial and operating metrics in order to measure our current performance and estimate our future performance. Our metrics may be calculated in a manner different than similar metrics used by other companies.
However, these investments negatively impact our GAAP Revenue, which is reported net of Consumer Incentives. 40 Non-GAAP Measures and Other Performance Metrics We regularly monitor a number of financial and operating metrics in order to measure our current performance and estimate our future performance. Our metrics may be calculated in a manner different than similar metrics used by other companies.
Research and Development Expense Research and development expense consists primarily of personnel costs of our information technology ("IT") engineering, IT architecture and product development teams, including salaries, benefits, bonuses, stock-based compensation and payroll taxes. Research and development expense also includes outsourcing costs, software licensing costs, professional fees and travel expenses.
Research and Development Expense Research and development expense consists primarily of personnel costs of our IT engineering, IT architecture and product development teams, including salaries, benefits, bonuses, stock-based compensation and payroll taxes. Research and development expense also includes outsourcing costs, software licensing costs, professional fees and travel expenses.
For a discussion of the year ended December 31, 2022 compared to the year ended December 31, 2021, please refer to Part II, Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report on Form 10-K for the year ended December 31, 2022.
For a discussion of the year ended December 31, 2023 compared to the year ended December 31, 2022, please refer to Part II, Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report on Form 10-K for the year ended December 31, 2023.
For a discussion of the year ended December 31, 2022, please refer to Part II, Item 7, "Management's Discussion and Analysis of Financial Condition and Liquidity and Capital Resources" in our Annual Report on Form 10-K for the year ended December 31, 2021.
For a discussion of the year ended December 31, 2023, please refer to Part II, Item 7, "Management's Discussion and Analysis of Financial Condition and Liquidity and Capital Resources" in our Annual Report on Form 10-K for the year ended December 31, 2022.
Some of these limitations are as follows: (1) Adjusted EBITDA does not reflect changes in, or cash requirements for, our working capital needs; (2) Adjusted EBITDA does not reflect the potentially dilutive impact of stock-based compensation; (3) Adjusted EBITDA does not reflect tax payments or receipts that may represent a reduction or increase in cash available to us and (4) other companies, including companies in our industry, may calculate Adjusted EBITDA or similarly titled measures differently, which reduces the usefulness of the metric as a comparative measure.
Some of these limitations are: (1) Adjusted EBITDA does not reflect changes in, or cash requirements for, our working capital needs; (2) Adjusted EBITDA does not reflect the potentially dilutive impact of stock-based compensation and equity instruments issued to our partners; (3) Adjusted EBITDA does not reflect tax payments or receipts that may represent a reduction or increase in cash available to us; and (4) other companies, including companies in our industry, may calculate adjusted EBITDA or similarly titled measures differently, which reduces the usefulness of the metric as a comparative measure.
Any lag between the timing of our payments to FI partners and our receipt of payment from marketers and their agencies can exacerbate our need for working capital during the first quarter of the calendar year. 59 Historical Cash Flows In this section, we discuss the activity of our cash flows for the year ended December 31, 2023 and the year ended December 31, 2022.
Any lag between the timing of our payments to FI partners and our receipt of payment from marketers and their agencies can exacerbate our need for working capital during the first quarter of the calendar year. 56 Historical Cash Flows In this section, we discuss the activity of our cash flows for the year ended December 31, 2024 and the year ended December 31, 2023.
We expect to incur additional operating losses as we continue our efforts to grow our business. We have historically financed our operations and capital expenditures through convertible note financings, private placements of our redeemable convertible preferred stock, public offerings of our common stock as well as lines of credit and term loans. As part of our acquisition of Bridg, Inc.
We expect to incur additional operating losses as we continue our efforts to grow our business. We have historically financed our operations and capital expenditures through convertible note financings, private placements of our redeemable convertible preferred stock, public offerings of our common stock as well as lines of credit and term loans.
By applying advanced analytics to the purchase data we receive, we make it actionable, helping marketers reach potential buyers at scale and measure the true sales impact of their marketing spend. We have strong relationships with leading marketers across a variety of industries, including retail, restaurant, travel and entertainment, direct-to-consumer, and grocery and gas.
By applying advanced analytics to the purchase data we receive, we make it actionable, helping marketers reach potential buyers at scale and measure the true sales impact of their marketing spend. We have strong relationships with leading marketers across a variety of industries, including everyday spend, specialty retail, restaurant, travel and entertainment.
Key Performance Metrics Year Ended December 31, in thousands except per user amounts 2023 2022 2021 Cardlytics MAUs 162,148 154,550 146,242 Cardlytics ARPU $ 1.91 $ 1.93 $ 1.83 Cardlytics Monthly Active Users ("MAUs") We define MAUs as targetable customers that have logged in and visited online or mobile applications containing offers, opened an email containing an offer, or redeemed an offer from the Cardlytics platform during a monthly period.
Key Performance Metrics Year Ended December 31, in thousands except per user amounts 2024 2023 2022 Cardlytics MAUs 166,943 162,148 154,550 Cardlytics ARPU $ 1.67 $ 1.91 $ 1.93 Cardlytics Monthly Active Users ("MAUs") We define MAUs as targetable customers that have logged in and visited online or mobile applications containing offers, opened an email containing an offer, or redeemed an offer from the Cardlytics platform during a monthly period.
Income Taxes Income taxes are accounted for using the asset and liability method. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective income tax bases, and operating loss and tax credit carry-forwards.
Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective income tax bases, and operating loss and tax credit carry-forwards.
The insertion orders state the terms of the arrangement, the negotiated fee, payment terms and the fixed period of time of the campaign. We invoice marketers monthly based on the qualifying purchases of our partners' customers as reported by our partners during the month.
The insertion orders state the terms of the arrangement, the negotiated fee, payment terms and the fixed period of time of the campaign. We generally invoice marketers monthly based on the qualifying purchases of our partners' customers as reported by our partners during the month or based on the engagement of our partners' customers with our offers during the month.
The change in our net operating assets and liabilities was primarily due to a $4.5 million increase in accounts receivable and contract assets, a $9.5 million decrease in other accrued expenses and a $1.7 million decrease in Partner Share liability, partially offset by a $1.4 million increase in our Consumer Incentive liability.
The change in our net operating assets and liabilities was primarily due to a $12.5 million increase in accounts receivable and contract assets, a $6.6 million decrease in other accrued expenses, and a $7.1 million decrease in our Consumer Incentive liability, partially offset by a $1.4 million decrease in prepaid expense and other assets and a $16.4 million increase in Partner Share liability.
The non-cash charges primarily related to stock-based compensation expense, depreciation and amortization expense (including the amortization of acquired intangible assets) impairment of goodwill and intangible assets, amortization of right-of-use assets, changes in the fair value of our contingent consideration, credit loss expense and income tax benefit.
The non-cash charges primarily related to stock-based compensation expense, depreciation and amortization expense (including the amortization of acquired intangible assets), impairment of goodwill and intangible assets, amortization of right-of-use assets, changes in contingent consideration, and credit loss expense.
We expect that general and administrative expenses will increase on an absolute dollar basis but decrease as a percentage of revenue as we focus on processes, systems and controls to enable our internal support functions to scale with the growth of our business. 50 Acquisition, Integration and Divestiture Costs Acquisition costs primarily represent diligence efforts, legal and advisory costs, broker fees and insurance premiums.
We expect that general and administrative expenses will decrease over time as a percentage of Revenue as we focus on processes, systems and controls to enable our internal support functions to scale with the growth of our business. Acquisition, Integration and Divestiture Costs (Benefit) Acquisition costs primarily represent diligence efforts, legal and advisory costs, broker fees and insurance premiums.
While our investment in our operations in the U.K. is not considered indefinitely invested, we do not plan to repatriate these funds. Through December 31, 2023, we have incurred accumulated net losses of $1,111.3 million since inception, including net losses of $134.7 million, $465.3 million and $128.6 million during 2023, 2022 and 2021, respectively.
While our investment in our operations in the U.K. is not considered indefinitely invested, we do not have any current plans to repatriate these funds. Through December 31, 2024, we have incurred accumulated net losses of $1,300.6 million since inception, including net losses of $189.3 million, $134.7 million and $465.3 million during 2024, 2023 and 2022, respectively.
Refer to Note 15—Segments to our consolidated financial statements for further details on our Adjusted Contribution by segment. 43 Adjusted EBITDA Adjusted EBITDA represents our Net Loss before income tax benefit; interest expense, net; depreciation and amortization; stock-based compensation expense; acquisition, integration and divestiture (benefits) costs; change in fair value of contingent consideration; foreign currency (gain) loss; impairment of goodwill and intangible assets; loss on divestiture; restructuring and reduction of force; income tax benefit; and deferred implementation costs.
Refer to Note 15—Segments to our consolidated financial statements for further details on our Adjusted Contribution by segment. 42 Adjusted EBITDA Adjusted EBITDA represents our Net Loss before interest expense, net; depreciation and amortization; stock-based compensation expense; foreign currency loss (gain); gain on debt extinguishment; acquisition, integration and divestiture costs (benefits); change in contingent consideration; impairment of goodwill and intangible assets, loss on divestiture; restructuring and reduction of force; income tax benefit and, in applicable periods, certain other income and expense items, such as deferred implementation costs.
Adjusted Net Loss We define Adjusted Net Loss as our Net Loss before stock-based compensation expense; foreign currency (gain) loss; acquisition, integration and divestitures costs (benefits); amortization of acquired intangibles; change in fair value of contingent consideration; impairment of goodwill and intangible assets; loss on divestiture; restructuring and reduction of force; and income tax benefit.
Adjusted Net Loss We define Adjusted Net Loss as our Net Loss before stock-based compensation expense; foreign currency loss (gain); acquisition, integration and divestiture costs (benefits); amortization of acquired intangibles; change in contingent consideration; impairment of goodwill and intangible assets; gain on debt extinguishment; loss on divestiture; restructuring and reduction of force; and income tax benefit, in applicable periods, certain other income and expense items.
Adjusted Contribution should be considered together with other operating and financial performance measures presented in accordance with GAAP. Also, Adjusted Contribution may not necessarily be comparable to similarly titled measures presented by other companies.
Adjusted Contribution should not be considered in isolation from, or as an alternative to, measures prepared in accordance with GAAP. Adjusted Contribution should be considered together with other operating and financial performance measures presented in accordance with GAAP. Also, Adjusted Contribution may not necessarily be comparable to similarly titled measures presented by other companies.
During 2022, we recognized $453.3 million of impairment of goodwill and intangible assets related to the Cardlytics and Bridg platforms. The impairment of goodwill and intangible assets resulted from a continued slowdown in the economy, decreased consumer spend, and a sustained decline in our stock price.
During 2023, we recognized $70.5 million of impairment of goodwill and intangible assets related to the Bridg platform. The impairment of goodwill and intangible assets resulted from a continued slowdown in the economy, decreased consumer spend, and a sustained decline in our stock price.
Refer to Note 4—Business Combinations to our consolidated financial statements for additional disclosures related to our acquisitions and divestitures. 60 Financing Activities Our cash flows used in financing activities have primarily been composed of contingent consideration payments to Bridg, repurchasing shares of our common stock, offset by borrowings and repayments under our debt facilities, proceeds from the issuance of common stock and payments for costs related to debt issuances and equity offerings.
Financing Activities Our cash flows used in financing activities have primarily been composed of contingent consideration payments to Bridg, repurchasing shares of our common stock, offset by borrowings and repayments under our debt facilities, proceeds from the issuance of common stock and payments for costs related to debt issuances and equity offerings.
Adjusted Contribution demonstrates how incremental revenue on our platforms generates incremental amounts to support our sales and marketing, research and development, general and administration and other investments. Adjusted Contribution is calculated by taking our total revenue less our Partner Share and other third-party costs exclusive of deferred implementation costs, which is a non-cash cost.
Adjusted Contribution demonstrates how incremental Revenue on our platforms generates incremental amounts to support our sales and marketing, research and development, general and administrative and other investments. Adjusted Contribution is calculated by taking our total Revenue less our Partner Share and other third-party costs.
The following table shows a summary of our cash flows for the periods presented (in thousands): Year Ended December 31, 2023 2022 Cash, cash equivalents and restricted cash at beginning of period $ 121,985 $ 233,562 Net cash used in operating activities (185) (53,904) Net cash used in investing activities (10,062) (15,760) Net cash used in financing activities (20,026) (39,987) Effect of exchange rates on cash, cash equivalents and restricted cash 118 (1,926) Cash, cash equivalents and restricted cash at end of period $ 91,830 $ 121,985 Operating Activities Historically, we have experienced negative operating cash flows, which reflects our investments to grow our business.
The following table shows a summary of our cash flows for the periods presented (in thousands): Year Ended December 31, 2024 2023 Cash, cash equivalents and restricted cash at beginning of period $ 91,830 $ 121,985 Net cash used in operating activities (8,824) (185) Net cash used in investing activities (18,746) (10,062) Net cash provided by (used in) financing activities 1,444 (20,026) Effect of exchange rates on cash, cash equivalents and restricted cash (110) 118 Cash, cash equivalents and restricted cash at end of period $ 65,594 $ 91,830 Operating Activities Historically, we have experienced negative operating cash flows, which reflects our investments to grow our business.
We expect that our Partner Share and other third-party costs will increase in absolute dollars as a result of our revenue growth. Delivery Costs Delivery costs consist primarily of personnel costs of our campaign, data operations and production support teams, including salaries, benefits, bonuses, stock-based compensation and payroll taxes.
We expect that our Partner Share and other third-party costs will fluctuate over time in connection with changes in our revenue. Delivery Costs Delivery costs consist primarily of personnel costs of our campaign, data operations and production support teams, including salaries, benefits, bonuses, stock-based compensation and payroll taxes.
Refer to Note 5—Goodwill and Acquired Intangibles to our condensed consolidated financial statements for additional information regarding the goodwill impairment. 55 Loss on divestiture Year Ended December 31, Change in thousands 2023 2022 $ % Loss on divestiture $ 6,550 $ — $ 6,550 n/a % of Revenue 2 % n/a On December 7, 2023 we sold and transferred substantially all of the assets of Entertainment for $6.0 million in cash, subject to a combined $1.1 million held in escrow for indemnities and sales and use taxes, as well as customary post-closing adjustment.
Loss on divestiture Year Ended December 31, Change in thousands 2024 2023 $ % Loss on divestiture $ — $ 6,550 $ (6,550) n/a % of Revenue — % 2 % On December 7, 2023 we sold and transferred substantially all of the assets of HSP EPI Acquisition, LLC ("Entertainment") for $6.0 million in cash, subject to a combined $1.1 million held in escrow for indemnities and sales and use taxes, as well as customary post-closing adjustment.
We do not consider these excluded items to be indicative of our core operating performance. The items that are non-cash include foreign currency gain (loss), impairment of goodwill and intangible assets, loss on divestiture, deferred implementation costs, depreciation and amortization, stock-based compensation expense and change in fair value of contingent consideration.
We do not consider these excluded items to be indicative of our core operating performance. Of these items depreciation and amortization expense, stock-based compensation expense, gain on debt extinguishment, impairment of goodwill and intangible assets and foreign currency loss (gain) are non-cash impacting.
The 2018 Loan Facility includes customary representations, warranties and covenants (affirmative and negative), including restrictive covenants that prohibit mergers, acquisitions, dispositions of assets, inccurrence of indebtedness, encumbrances on our assets and the payment or declaration of dividends, in each case subject to specified exceptions.
We also confirmed the extension of the maturity date of the loan to April 29, 2025 based on our positive Adjusted EBITDA result. 55 The 2018 Loan Facility includes customary representations, warranties and covenants (affirmative and negative), including restrictive covenants that prohibit mergers, acquisitions, dispositions of assets, incurrence of indebtedness, encumbrances on our assets and the payment or declaration of dividends, in each case subject to specified exceptions.
Results of Non-GAAP Measures Billings Year Ended December 31, Change Year Ended December 31, Change in thousands 2023 2022 $ % 2022 2021 $ % Billings $ 453,426 $ 442,477 10,949 2 $ 442,477 $ 394,075 48,402 12 Billings increased by $10.9 million during 2023 compared to 2022, primarily driven by an increase of $32.8 million in sales to new marketers, offset by a $21.9 million net decrease in sales to existing marketers.
Results of Non-GAAP Measures Billings Year Ended December 31, Change Year Ended December 31, Change in thousands 2024 2023 $ % 2023 2022 $ % Billings $ 443,840 $ 453,426 (9,586) (2) $ 453,426 $ 442,477 10,949 2 Billings decreased by $9.6 million during 2024 compared to 2023, primarily driven by an increase of $45.7 million in sales to new marketers, offset by a $55.3 million net decrease in sales to existing marketers.
Operating activities used $53.9 million of cash in 2022, which reflected our net loss of $465.3 million, $422.7 million of which were non-cash charges, and a $11.3 million change in our net operating assets and liabilities.
Operating activities used $8.8 million of cash in 2024, which reflected our net loss of $189.3 million, $196.3 million of which were non-cash charges, and a $15.8 million change in our net operating assets and liabilities.
Impairment of goodwill and intangible assets Year Ended December 31, Change in thousands 2023 2022 $ % Impairment of goodwill and intangible assets $ 70,518 $ 453,288 $ (382,770) (84) % % of Revenue 23 % 152 % During 2023, we recognized $70.5 million of impairment of goodwill and intangible assets related to the Bridg platform.
Impairment of goodwill and intangible assets Year Ended December 31, Change in thousands 2024 2023 $ % Impairment of goodwill and intangible assets $ 131,595 $ 70,518 $ 61,077 87 % % of Revenue 47 % 23 % During 2024, we recognized $131.6 million of impairment of goodwill and intangible assets related to the Bridg platform.
Cardlytics ARPU increased by $0.10 during 2022 compared to 2021 as a result of a $31.4 million increase in revenue and an 8.3 million increase in Cardlytics MAUs. 42 Non-GAAP Metrics Year Ended December 31, in thousands 2023 2022 2021 Revenue $ 309,204 $ 298,542 $ 267,116 Billings $ 453,426 $ 442,477 $ 394,075 Gross Profit $ 130,378 $ 112,632 $ 103,340 Adjusted Contribution $ 158,626 $ 143,035 $ 129,628 Net Loss $ (134,702) $ (465,264) $ (128,565) Adjusted EBITDA $ 3,771 $ (45,169) $ (12,220) Adjusted Net Loss $ (11,436) $ (60,250) $ (38,727) Net cash used in operating activities $ (185) $ (53,904) $ (38,523) Free Cash Flow $ (12,577) $ (67,390) $ (51,087) Definitions of Non-GAAP Measures Billings Billings represents the gross amount billed to customers and marketers for services in order to generate revenue.
Cardlytics ARPU decreased by $0.02 during 2023 compared to 2022 as a result of a $0.3 million increase in Consumer Incentives due to changes to our targeting and ranking system that led to higher engagement. 41 Non-GAAP Metrics Year Ended December 31, in thousands 2024 2023 2022 Revenue $ 278,298 $ 309,204 $ 298,542 Billings $ 443,840 $ 453,426 $ 442,477 Gross Profit $ 120,894 $ 130,378 $ 112,632 Adjusted Contribution $ 150,537 $ 158,626 $ 143,035 Net Loss $ (189,304) $ (134,702) $ (465,264) Adjusted EBITDA $ 2,523 $ 3,771 $ (45,169) Adjusted Net Loss $ (18,909) $ (11,436) $ (60,250) Net cash used in operating activities $ (8,824) $ (185) $ (53,904) Free Cash Flow $ (28,122) $ (12,577) $ (67,390) Definitions of Non-GAAP Measures Billings Billings represents the gross amount billed to customers and marketers for services in order to generate revenue.
Financing activities used $20.0 million in cash in 2023, consisting of $50.1 million paid for the First Anniversary Payment, partially offset by $30.0 million borrowed under our 2018 Line of Credit. Financing activities used $40.0 million in cash in 2022, consisting of $40.0 million used to repurchase shares of our common stock.
Financing activities used $20.0 million in cash in 2023, consisting of $50.1 million paid for the First Anniversary Payment, partially offset by $30.0 million borrowed under our 2018 Line of Credit. Critical Accounting Estimates Our consolidated financial statements are prepared in accordance with GAAP.
For the periods presented, income tax benefit represents the release of a portion of our valuation allowance in connection with deferred tax liabilities arising from our acquisitions of Dosh and Bridg. 51 Results of Operations The following table sets forth our consolidated statements of operations (in thousands): Year Ended December 31, 2023 2022 2021 Revenue $ 309,204 $ 298,542 $ 267,116 Costs and expenses: Partner Share and other third-party costs 150,578 155,507 141,273 Delivery costs 28,248 30,403 22,503 Sales and marketing expense 57,425 74,745 65,996 Research and development expense 51,352 54,435 38,104 General and administrative expense 58,810 81,446 66,222 Acquisition, integration and divestiture (benefits) costs (6,313) (2,874) 24,372 Change in fair value of contingent consideration 1,246 (128,174) 1,374 Impairment of goodwill and intangible assets 70,518 453,288 — Loss on divestiture 6,550 — — Depreciation and amortization expense 26,460 37,544 29,871 Total costs and expenses 444,874 756,320 389,715 Operating loss (135,670) (457,778) (122,599) Other income (expense): Interest expense, net (2,336) (2,556) (12,563) Foreign currency gain (loss) 3,304 (6,376) (1,267) Total other income (expense) 968 (8,932) (13,830) Loss before income taxes (134,702) (466,710) (136,429) Income tax benefit — 1,446 7,864 Net Loss $ (134,702) $ (465,264) $ (128,565) Comparison of Years Ended December 31, 2023 and 2022 In this section, we discuss the results of our operations for the year ended December 31, 2023 compared to the year ended December 31, 2022.
These are primarily non-cash and are associated with debt payment transactions which are non-recurring. 48 Results of Operations The following table sets forth our consolidated statements of operations (in thousands): Year Ended December 31, 2024 2023 2022 Revenue $ 278,298 $ 309,204 $ 298,542 Costs and expenses: Partner Share and other third-party costs 127,761 150,578 155,507 Delivery costs 29,643 28,248 30,403 Sales and marketing expense 52,649 57,425 74,745 Research and development expense 49,607 51,352 54,435 General and administrative expense 56,482 58,810 81,446 Acquisition, integration and divestiture costs (benefits) 161 (6,313) (2,874) Change in contingent consideration 210 1,246 (128,174) Impairment of goodwill and intangible assets 131,595 70,518 453,288 Loss on divestiture — 6,550 — Depreciation and amortization expense 25,689 26,460 37,544 Total costs and expenses 473,797 444,874 756,320 Operating loss (195,499) (135,670) (457,778) Other income (expense): Interest expense, net (5,553) (2,336) (2,556) Foreign currency (loss) gain (1,269) 3,304 (6,376) Gain on debt extinguishment 13,017 — — Total other income (expense) 6,195 968 (8,932) Loss before income taxes (189,304) (134,702) (466,710) Income tax benefit — — 1,446 Net Loss (189,304) (134,702) (465,264) Net loss per share, basic and diluted $ (3.91) $ (3.69) $ (13.92) Weighted-average common shares outstanding, basic and diluted 48,361 36,488 33,419 Comparison of Years Ended December 31, 2024 and 2023 In this section, we discuss the results of our operations for the year ended December 31, 2024 compared to the year ended December 31, 2023.
Investing activities used cash totaling $10.1 million and $15.8 million, in 2023 and 2022, respectively. Our investing cash outflows during these periods primarily consisted of funds used for the purchases of technology hardware and costs to develop internal-use software.
Our investing cash outflows during these periods primarily consisted of funds used for the purchases of technology hardware and costs to develop internal-use software. Additionally, in 2024 and 2023, we had cash inflows of $0.6 million and $2.3 million, respectively, related to proceeds from divestitures, net of cash divested.
Liquidity and Capital Resources The following table summarizes our cash and cash equivalents, restricted cash, working capital, accounts receivable and contract assets, net and unused available borrowings (in thousands): December 31, 2023 2022 Cash and cash equivalents $ 91,830 $ 121,905 Restricted cash — 80 Working capital (1) 52,779 1,098 Accounts receivable and contract assets, net 120,622 115,609 Unused available borrowings 16,688 60,000 (1) We define working capital as current assets less current liabilities.
Refer to Note 9—Debt and Financing Arrangements to our consolidated financial statements for additional information regarding the 2020 Convertible Senior Notes. 53 Liquidity and Capital Resources The following table summarizes our cash and cash equivalents, restricted cash, working capital, accounts receivable and contract assets, net and unused available borrowings (in thousands): December 31, 2024 2023 Cash and cash equivalents $ 65,594 $ 91,830 Working capital (1) 29,028 52,779 Accounts receivable and contract assets, net 103,252 120,622 Unused available borrowings (2) 60,000 16,688 (1) We define working capital as current assets less current liabilities.
Stock-based Compensation Expense The following table summarizes the allocation of stock-based compensation in the consolidated statements of operations (dollars in thousands): Year Ended December 31, Change 2023 2022 $ % Delivery costs $ 2,427 $ 2,682 $ (255) (10) % Sales and marketing expense 12,624 11,935 689 6 Research and development expense 16,392 13,262 3,130 24 General and administrative expense 9,537 16,807 (7,270) (43) Total stock-based compensation expense $ 40,980 $ 44,686 $ (3,706) (8) % % of Revenue 13 % 15 % 54 Stock-based compensation expense decreased by $3.7 million during 2023 compared to 2022 primarily driven by the reversal of the 2021 PSUs and higher forfeitures related to executive departures that occurred in 2023.
Stock-based Compensation Expense The following table summarizes the allocation of stock-based compensation in the consolidated statements of operations (dollars in thousands): Year Ended December 31, Change 2024 2023 $ % Delivery costs $ 2,680 $ 2,427 $ 253 10 % Sales and marketing expense 10,017 12,624 (2,607) (21) Research and development expense 14,957 16,392 (1,435) (9) General and administrative expense 12,713 9,537 3,176 33 Total stock-based compensation expense $ 40,367 $ 40,980 $ (613) (1) % % of Revenue 15 % 13 % Stock-based compensation expense decreased by $0.6 million during 2024 compared to 2023.
Revenue Year Ended December 31, Change in thousands 2023 2022 $ % Billings $ 453,426 $ 442,477 $ 10,949 2 % Consumer Incentives 144,222 143,935 287 — Revenue $ 309,204 $ 298,542 $ 10,662 4 % % of billings 68 % 67 % The $10.7 million increase in revenue during 2023 compared to 2022 was comprised of a $10.9 million increase in billings, offset by a $0.3 million increase in Consumer Incentives.
Revenue Year Ended December 31, Change in thousands 2024 2023 $ % Billings $ 443,840 $ 453,426 $ (9,586) (2) % Consumer Incentives 165,542 144,222 21,320 15 Revenue $ 278,298 $ 309,204 $ (30,906) (10) % % of Billings 63 % 68 % 49 The $30.9 million decrease in Revenue during 2024 compared to 2023 was comprised of a $9.6 million decrease in Billings and a $21.3 million increase in Consumer Incentives.
Delivery Costs Year Ended December 31, Change in thousands 2023 2022 $ % Delivery costs excluding stock-based compensation expense and restructuring and reduction of force $ 25,821 $ 25,860 $ (39) — % Plus: Stock-based compensation expense 2,427 2,682 (255) (10) Restructuring and reduction of force — 1,861 (1,861) (100) Total delivery costs $ 28,248 $ 30,403 $ (2,155) (7) % % of Revenue 9 % 10 % Delivery costs decreased by $2.2 million during 2023 compared to the 2022 .
Delivery Costs Year Ended December 31, Change in thousands 2024 2023 $ % Delivery costs excluding stock-based compensation expense $ 26,963 $ 25,821 $ 1,142 4 % Plus: Stock-based compensation expense 2,680 2,427 253 10 Total delivery costs $ 29,643 $ 28,248 $ 1,395 5 % % of Revenue 11 % 9 % Total delivery costs increased by $1.4 million during 2024 compared to 2023 .
See our consolidated financial statements for further details regarding our current assets and current liabilities. Our cash and cash equivalents are available for working capital purposes. We do not enter into investments for trading purposes, and our investment policy is to invest any excess cash in short-term, highly liquid investments that limit the risk of principal loss.
We do not enter into investments for trading purposes, and our investment policy is to invest any excess cash in short-term, highly liquid investments that limit the risk of principal loss. Currently, a significant portion of our cash and cash equivalents are held in fully FDIC-insured money market accounts, demand deposit accounts and U.S. Treasury Bills.
Our reporting units are one level below the operating segments at which level our segment management conducts regular reviews of the operating results. 61 Our impairment evaluation consists of a qualitative assessment. If this assessment indicates that the fair value of the reporting unit is not more likely than not less than the carrying amount, goodwill is not considered impaired.
Our impairment evaluation consists of a qualitative assessment. If this assessment indicates that the fair value of the reporting unit is not more likely than not less than the carrying amount, goodwill is not considered impaired. Otherwise, a quantitative impairment test is performed by comparing the estimated fair value of a reporting unit to its carrying value, including goodwill.
Year Ended December 31, Change Year Ended December 31, Change in thousands 2023 2022 # % 2022 2021 # % Cardlytics MAUs 162,148 154,550 7,598 5 154,550 146,242 8,308 6 Cardlytics MAUs increased by 7.6 million during 2023 compared to 2022 primarily driven by an increase in new MAUs (41% of total growth) and lapsed customers returning (59% of total growth).
Year Ended December 31, Change Year Ended December 31, Change in thousands 2024 2023 # % 2023 2022 # % Cardlytics MAUs 166,943 162,148 4,795 3 162,148 154,550 7,598 5 Cardlytics MAUs increased by 4.8 million during 2024 compared to 2023, primarily driven by organic growth of the existing FI partners in the U.K. and U.S. and a new FI Partner in the U.K.
If the carrying value of the net assets associated with the reporting unit exceeds the fair value of the reporting unit, goodwill is considered impaired and the impairment will be determined as the amount by which the reporting unit's carrying value exceeds its fair value, not to exceed the carrying amount of goodwill.
If the carrying value of the net assets associated with the reporting unit exceeds the fair value of the reporting unit, goodwill is considered impaired and the impairment will be determined as the amount by which the reporting unit's carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. 58 We assessed the triggering events criteria along with related conditions and developments as of September 30, 2024, and we concluded that we had a triggering event as a result of a sustained decline in our stock price during the three months ended September 30, 2024.
Sales and marketing expense excluding stock-based compensation and restructuring and reduction of force decreased by $15.9 million primarily due to a $10.7 million decrease in headcount , a $2.4 million decrease in marketing events, a $1.8 million decrease in professional fees, a $0.5 million decrease in facility expense, a $0.3 million decrease in software licensing costs and a $0.2 million decrease in travel expenses. 53 Research and Development Expense Year Ended December 31, Change in thousands 2023 2022 $ % Research and development expense excluding stock-based compensation expense and restructuring and reduction of force $ 34,960 $ 39,573 $ (4,613) (12) % Plus: Stock-based compensation expense 16,392 13,262 3,130 24 Restructuring and reduction of force — 1,600 (1,600) (100) Total research and development expense $ 51,352 $ 54,435 $ (3,083) (6) % % of Revenue 17 % 18 % Research and development expense decreased by $3.1 million during 2023 compared to 2022.
Sales and marketing expenses excluding stock-based compensation decreased by $2.2 million during 2024 compared to 2023 primarily due to a $2.2 million decrease in staff expenses, mostly related to the divestiture of entertainment in December 2023, a $0.3 million decrease in training, dues and subscriptions expenses, and a $0.3 million decrease in travel and entertainment, partially offset by a $0.5 million increase in marketing events and a $0.1 million increase in software licenses. 50 Research and Development Expense Year Ended December 31, Change in thousands 2024 2023 $ % Research and development expense excluding stock-based compensation expense $ 34,650 $ 34,960 $ (310) (1) % Plus: Stock-based compensation expense 14,957 16,392 (1,435) (9) Total research and development expense $ 49,607 $ 51,352 $ (1,745) (3) % % of Revenue 18 % 17 % Total research and development expenses decreased $1.7 million in 2024 compared to 2023.
Year Ended December 31, Change Year Ended December 31, Change 2023 2022 $ % 2022 2021 $ % Cardlytics ARPU $ 1.91 $ 1.93 (0.02) (1) $ 1.93 $ 1.83 0.10 5 Cardlytics ARPU decreased by $0.02 during 2023 compared to 2022 as a result of a $10.7 million increase in revenue and a 7.6 million increase in Cardlytics MAUs.
Year Ended December 31, Change Year Ended December 31, Change 2024 2023 $ % 2023 2022 $ % Cardlytics ARPU $ 1.67 $ 1.91 (0.24) (13) $ 1.91 $ 1.93 (0.02) (1) Cardlytics ARPU decreased by $0.24 during 2024 compared to 2023 as a result of a $21.3 million increase in Consumer Incentives due to changes to our targeting and ranking system that led to higher engagement.
Research and development expense excluding stock-based compensation and restructuring and reduction of force decreased by $4.6 million primarily due to a $5.9 million decrease in headcount, a $1.5 million increase in capital development and a $0.5 million tax benefit, partially offset by a $2.4 million increase in non staff software licensing and data storage costs related to operations and a $0.9 million increase in professional fees.
Research and development expenses excluding stock-based compensation decreased by $0.3 million during 2024 compared to 2023, primarily due to a $0.8 million decrease in professional fees, a $0.3 million decrease in administrative expenses, and a $0.2 million decrease in staff expenses partially offset by a $1.0 million increase in data storage and data center expense.
Foreign Currency Gain (Loss) Year Ended December 31, Change in thousands 2023 2022 $ % Foreign currency gain (loss) $ 3,304 $ (6,376) $ 9,680 (152) % % of Revenue 1 % (2) % Foreign currency gain (loss) was $3.3 million during 2023 compared to foreign currency loss of $6.4 million during 2022, primarily due to the decrease in the value of the British pound relative to the U.S. dollar. 56 Income Tax Benefit Year Ended December 31, Change in thousands 2023 2022 $ % Income tax benefit $ — $ 1,446 $ (1,446) (100) % % of Revenue — % — % Income tax benefit was $1.4 million during 2022 due to the release of a portion of our valuation allowance in connection with deferred tax liabilities arising from our acquisitions of Dosh and Bridg.
Foreign Currency (Loss) Gain Year Ended December 31, Change in thousands 2024 2023 $ % Foreign currency (loss) gain $ (1,269) $ 3,304 $ (4,573) (138) % % of Revenue — % 1 % Foreign currency loss was $1.3 million during 2024 compared to a gain of $3.3 million during 2023, primarily due to the change in the value of the British pound relative to the U.S. dollar.